Volume 2.45 | Dec 9

Prostate Cell News 2.45, December 9, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Identification of Novel CHD1-Associated Collaborative Alterations of Genomic Structure and Functional Assessment of CHD1 in Prostate Cancer
Researchers report the identification of CHD1 as one of the most frequently homozygously deleted genes in prostate cancer, second only to PTEN in this regard. [Oncogene] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Selective Inhibitory Effect of HPMA Copolymer-Cyclopamine Conjugate on Prostate Cancer Stem Cells
Here, researchers designed an HPMA (N-(2-hydroxypropyl)methacrylamide)-based cyclopamine delivery system as a cancer stem cell-selective macromolecular therapeutic with improved drug solubility and decreased systemic toxicity. [Biomaterials] Abstract

Profiling of Antibody Production Against Xenograft-Released Proteins by Protein Microarrays Discovers Prostate Cancer Markers
This study describes a novel xenograft-based biomarker discovery platform and proves its usefulness in the discovery of serum markers for prostate cancer. [J Proteome Res] Abstract

FOXA1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castrate-Resistant Prostate Cancer
Researchers investigated the correlation of forkhead box protein A1 (FOXA1) expression with clinical parameters, prostate-specific antigen relapse-free survival, and hormone receptor expression in a large cohort of prostate cancer patients at different disease stages. [Am J Pathol] Abstract

Progression of Prostate Carcinogenesis and Dietary Methyl Donors: Temporal Dependence
Researchers looked at the effect of excess methyl donors on the growth rate of prostate cancer (PCa) in vivo, the ability of 5-aza-2′-deoxycytidine to demethylate in the presence of excess dietary methyl donors and the effect of in utero feeding of excess methyl donors to the later onset of PCa. [Cancer Prev Res] Abstract

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
Here researchers provide the first evidence for an ERG-mediated PIM1 up-regulation in prostate cells in vitro and in vivo, suggesting a direct effect of ERG transcriptional activity in the alteration of genetic stability. [PLoS One] Abstract

Caveolin-1 Upregulation Contributes to c-Myc-Induced High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer
Researchers’ results suggest that caveolin-1 is associated with c-Myc in the development of high-grade prostatic intraepithelial neoplasia and prostate cancer. [Mol Cancer Res] Abstract

MiR-146a Suppresses Tumor Growth and Progression by Targeting EGFR Pathway and in a p-ERK-Dependent Manner in Castration-Resistant Prostate Cancer
Given the emerging roles of microRNA (miRNA) as a key regulator of castration-resistant prostate cancer (CRPC) researchers postulated that miRNA may play a significant role in CRPC formation. [Prostate] Abstract

Hsp90 Inhibitor 17-AAG Inhibits Progression of LuCaP35 Xenograft Prostate Tumors to Castration Resistance
This study addresses whether targeting heat shock protein 90 (Hsp90) regulation of androgen receptor can inhibit prostate cancer progression to castration resistance. [Prostate] Abstract

Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo
The present study was designed to determine the role of inhibitor of apoptosis family proteins in phenethyl isothiocyanate-induced apoptosis induction. [Prostate] Abstract

TMPRSS2ERG-Specific Transcriptional Modulation Is Associated with Prostate Cancer Biomarkers and TGF-Beta Signaling
Researchers studied large-scale gene expression profiles in 47 prostate tumor tissue samples and in 48 normal prostate tissue samples taken from the non-suspect area of clinical low-risk tumors using Affymetrix GeneChip Exon 1.0 ST microarrays. [BMC Cancer] Abstract


Discrepancy in Prostate Cancer Localization between Biopsy and Prostatectomy Specimens in Patients with Unilateral Positive Biopsy: Implications for Focal Therapy
Scientists evaluated the discrepancy in prostate cancer localization between unilateral positive biopsy and radical prostatectomy. [Prostate] Abstract

Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer Among High-Risk Men Enrolled in Prostate Cancer Early Detection
Scientists evaluated clinical information from six polymorphisms associated with early-onset prostate cancer (PCA) in a longitudinal cohort of high-risk men enrolled in PCA early detection with significant African American participation. [Cancer Epidemiol Biomarkers Prev] Abstract

Correlations Among Cardiovascular Risk Factors, Prostate Blood Flow, and Prostate Volume in Patients with Clinical Benign Prostatic Hyperplasia
The objective of this study was to investigate the relationships among the cardiovascular risk factors, prostate blood flow, and prostate volume in patients with clinical benign prostatic hyperplasia. [Urology] Abstract

View Nature.com Webcast: Current Controversies - HIV Vaccines

Lloyd J. Old, M.D., Father of Modern Tumor Immunology, Dies at 78 of Prostate Cancer
The Cancer Research Institute (CRI) announced that CRI founding scientific and medical director Lloyd J. Old, M.D., regarded as the “Father of Modern Tumor Immunology,” died at his home in New York City from prostate cancer. [Cancer Research Institute] Press Release

Clarient and ACORN Research Announce a Collaboration to Standardize Testing of Most Common Cancers
Clarient, Inc. and ACORN Research LLC announced their strategic collaboration around molecular testing of tumor samples. The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities. [Business Wire] Press Release
Panel Endorses Active Monitoring and Delay of Treatment for Low-Risk Prostate Cancer
An independent panel convened by the National Institutes of Health has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression. [National Institutes of Health, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW European School of Oncology – Active Surveillance for Low Risk Prostate Cancer
January 12-13, 2012
Rotterdam, Netherlands

our events page to see a complete list of events in the prostate cell community.

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoc – Prostate Cancer (Weill Cornell Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us